More than half of the patients with advanced liver cancer evaluated have survived more than a year after treatment with an immunotherapeutic drug (nivolumab), supplied in a research developed by the Clinical University of Navarre (CUN) and the CIMA. The trial Has been led by Dr. Bruno Sangro, director of Hepatology at the University of Navarra Clinic, and Ignacio Melero, co-director of the Immunology and Immunotherapy Service of the Clinic and researcher at the Center for Applied Medical Research (CIMA) at the University of Navarra.